Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cabazitaxel in High Risk Prostate Cancer
NCT01941550Phase 2Terminated
- Sponsor
- RWTH Aachen University
- Start
- Jul 2013
- Primary completion
- Jan 2016
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel in prostate cancer (PCa), sponsored by RWTH Aachen University. Started Jul 2013; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01941550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01941550.